Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (11083)	3/28/2017 2:45:08 PM
From: tuck	Read Replies (1) \| Respond to of 12215

That's a question for the entire oral program, IMO. Given the much lower bioavailability of the oral formulation, are they going to be able to get sufficient receptor occupancy to keep the benign AE profile? I noted that while dizziness and headache did not seem to show dose response in this trial, paraesthesia and somnolence did (again, as you point out, small n). Does this imply that the former are on target effects, but the latter are not? I haven't studied the data on the target enough to say. If that were true, might we expect a more exaggerated version of this AE profile in the oral trials? I.E. same level of dizziness and headache, but more paraesthesia and somnolence? I forgot to mention the the CMO said patient perception of dizziness can in part be secondary to paraesthesia. In other words, he seemed to suggest that it's natural to feel a bit a dizziness when your face tingles. Muddies the issue a bit. Cheers, Tuck